FDA clears Sanofi's Infilbray, first Gaucher drug that reaches the brain
Sanofi's Infilbray just became the first US-approved medicine for the neurological symptoms of type 3 Gaucher disease — and the first that can cross into the brain. The FDA cleared the once-daily pill for adults and children weighing at least 15 kg, though it flagged serious psychiatric risks.
- 3 sources report it: ibtimes.co.uk, finance.yahoo.com, marketwatch.com.
- The source published it on Nov 18, 2026 at 9:47 PM.
Nothing open. Every check passed.
The FDA approved Sanofi's Infilbray on Wednesday, making it the first treatment in the US cleared for the neurological symptoms of type 3 Gaucher disease. The oral medicine is also the first for the rare inherited disorder that can cross into the brain. Until now, enzyme replacement therapy could only address effects outside the brain and nervous system, while fatty substances kept building up in the brain — leaving patients struggling with balance, coordination, speech, memory and thinking.
The decision rests on a late-stage trial of 43 people whose symptoms outside the brain and nervous system had already stabilised on enzyme replacement therapy. One group kept receiving that treatment every two weeks; the other took Infilbray by mouth once a day. After 52 weeks, the Infilbray group had improved on a combined measure of muscle control, movement coordination and thinking.
That combined score has a catch: it doesn't show how much of the difference came from movement versus thinking, so patients whose main problem is speaking or remembering get no separate estimate of their own improvement. The trial enrolled people aged 12 and older. Children under 12 can still meet the FDA's weight threshold of 15 kilograms (about 33 pounds), but they weren't part of the study the agency relied on.
The label comes with warnings. The FDA listed digestive problems and mood changes among the most common side effects, and cautioned that patients could experience serious psychiatric effects, including suicidal thoughts and behaviour. Animal studies also raised the possibility of clouded vision in younger patients and the risk that exposure during pregnancy could harm a developing foetus.
Infilbray works differently from Sanofi's existing Gaucher lineup. Its active ingredient, venglustat, cuts how much of the fatty substances the body produces, rather than replacing a missing enzyme the way Cerezyme does — Cerezyme is Sanofi's treatment for type 1 and type 3 disease, while Cerdelga is its type 1 medicine. The approval expands Sanofi's Gaucher portfolio as new chief executive Belén Garijo looks to cut the company's reliance on Dupixent, the asthma drug expected to lose key patent protection by the early 2030s, according to Reuters. Regulators in the European Union and Japan are also reviewing Infilbray for type 3 Gaucher disease, Sanofi said.
Story timeline
New source confirms the story: marketwatch.com.
TopicsSanofi · Infilbray · FDA · Cerezyme · Cerdelga · venglustat · Belén Garijo · Dupixent
Written by AI from verified reporting.
More stories
- Health & science news24.com.au 0 viewsActinogen trial: Alzheimer's drug slows decline by 30pc in over-75s
- Health & science finance.yahoo.com 6 sources 1 viewFDA clears Regeneron's Livsayis, a gMG shot dosed four times a year
- Health & science cardiovascularbusiness.com 1 viewFDA moves to yank liquid statin FloLipid off US shelves
- Health & science cnbc.com Caught by @bayu.lestari45 1 viewFDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant

